Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

NICE recommends blood cancer drug be made routinely available on the NHS following new CDF data collection

NICE has recommended that brentuximab vedotin be made available for more people with CD-30 positive Hodgkin lymphoma after a Cancer Drugs Fund (CDF) data collection.

NICE has recommended that brentuximab vedotin be made available for more people with CD-30 positive Hodgkin lymphoma after a Cancer Drugs Fund (CDF) data collection. Brentuximab vedotin has been reassessed by NICE after an earlier recommendation calling for more evidence to be gathered on the drug’s value from patients who benefitted from it via the CDF. Meindert Boysen, director of the NICE centre for health technology evaluation, said: €œStem cell therapy gives people with Hodgkin lymphoma the best chance of survival but many will not be fit enough to have this and for them options are limited. We are delighted

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy